<DOC>
	<DOCNO>NCT00682656</DOCNO>
	<brief_summary>The adequate treatment American tegumentary leishmaniasis crucial since disease , differently cause Old World species , painful self-healing may lead disfigure mucosal involvement . So far , pentavalent antimony compound consider treatment choice cutaneous leishmaniasis ( CL ) , however , drug present high frequency side effect important disadvantage parenteral administration need careful renal cardiac monitoring . Azithromycin macrolide antibiotic , non-expensive , largely commercially available show in-vitro vivo activity different specie Leishmania . The main objective study evaluate efficacy safety oral azithromycin treatment CL . The efficacy oral treatment azithromycin 500 mg/day 20 day go compare standard treatment intramuscular injection 20 mg/Kg/day pentavalent antimonials ( GlucantimeÂ® ) 20 day patient CL two endemic region Brazil : metropolitan region Belo Horizonte Montes Claros ( MG ) southeast Brazil Corte de Pedras ( Bahia ) , Northeastern Brazil . The patient follow last 12 month .</brief_summary>
	<brief_title>Safety Efficacy Azithromycin Treat Cutaneous Leishmaniasis</brief_title>
	<detailed_description>Included new site ( University Estadual de Montes Claros - UNIMONTES ) 7 June 2010 . The site include due need achieve patient . The ANVISA ( National Agency Sanitary Surveillance ) approve site March 2011 start activity plan June 2011 .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Patients older 14 young 65 year old Skin lesion clinical suggestion cutaneous leishmaniasis positive leishmanin skin test ( Montenegro test ) parasitological ( direct observation leishmania amastigotes , leishmania vitro culture aspirate , histopathological ) molecular ( Polymerase Chain Reaction PCR ) sample . No use oral potentially antileishmanial drug , topic throughout term current injury . Absence disseminate leishmaniasis . Absence mucosal involvement . Agreement participate study sign informed consent . Diabetes mellitus , kidney disease , liver cardiac disease , tuberculosis , malaria . Pregnancy lactate mother Breast feed Cutaneous lesion bacterial infection antibiotic need prescribe More six cutaneous lesion Previous history cutaneous mucosal leishmaniasis Use drug potential pharmacological interaction antimonials antiarrhythmic tricycle antidepressives Previous intolerance azithromycin macrolides Nmethylglucamine Abusive alcohol ingestion accord CAGE questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>cutaneous leishmaniasis</keyword>
	<keyword>azithromycin</keyword>
	<keyword>N- methyl glucamine</keyword>
</DOC>